Results 91 to 100 of about 1,993,131 (236)

Effect of renal denervation for patients with isolated systolic hypertension: a systematic review and meta-analysis. [PDF]

J Geriatr Cardiol, 2023
Li L, Xiong YL, Tu B, Liu SY, Zhang ZH, Hu Z, Yao Y.   +6 more
europepmc   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Association of isolated systolic, isolated diastolic, and systolic-diastolic masked hypertension with carotid artery intima-media thickness

, 2015
\ua9 2014 Wiley Periodicals, Inc. Masked hypertension (MH) is associated with advanced target organ damage. However, patients with MH constitute a group of individuals with heterogeneous characteristics concerning their ambulatory blood pressure (BP ...
Vemmos K, Koroboki E, Stamatelopoulos K, Michas F, Stellos K, Zakopoulos N, Tsouma I, Manios E   +7 more
core   +5 more sources

Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial. [PDF]

Am Heart J, 2022
Wang SY, Hanna JM, Gongal P, Onuma OK, Nanna MG.   +4 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Identification of phenotypes at risk of transition from diastolic hypertension to isolated systolic hypertension

, 2015
Little is known about the potential progression of hypertensive patients towards isolated systolic hypertension (ISH) and about the phenotypes associated with the development of this condition.
ESPOSITO, GIOVANNI, IZZO, RAFFAELE, STABILE, EUGENIO, DE SIMONE, GIOVANNI, ESPOSITO, roberta, DE LUCA, NICOLA, ROZZA, FRANCESCO, GALDERISI, MAURIZIO, DE MARCO, MARINA, TRIMARCO, VALENTINA   +9 more
core   +1 more source

The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients. [PDF]

J Clin Med, 2022
Gao M, Lin W, Ma T, Luo Y, Xie H, Cheng X, Bai Y.   +6 more
europepmc   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Prevalence of hypertension-mediated target organ damage in hypertensive patients in an outpatient setting – An observational study

International Journal of Noncommunicable Diseases
Aim: We aimed to study the clinical profile of hypertensive patients in an outpatient setting and to assess the burden and pattern of hypertension-mediated target organ damage (HMOD). Materials and Methods: A prospective observational study evaluated the
Ajay Jaryal, Bhupender Kumar, Nripen Gaur, Kapil Sharma, Sanjay Vikrant, Nitin Kumar   +5 more
doaj   +1 more source